(KVUE) Kenvue Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(KVUE) Kenvue Inc. Bundle
Download Your Competitive Advantage
This Kenvue Inc. BCG Matrix helps you see how the company’s products or business units are positioned across Stars, Cash Cows, Question Marks, and Dogs for strategy and portfolio analysis. The page already shows a real preview of the report, so you can review the actual format and content before purchase. Buy the full version to get the complete ready-to-use analysis.
Stars
Neutrogena, premium skin care
Neutrogena fits a Star in Kenvue Inc.'s BCG Matrix: premium skin care still grows faster than mature OTC, and the brand keeps strong shelf space across face, body, and sun care. Kenvue reported 2025 net sales of $15.5 billion, with Skin Health and Beauty remaining a key growth engine. That mix supports share and growth at the same time.
Aveeno, oat-based skin health
Aveeno stays a core Kenvue skin-health brand, backed by dermatologist-led trust and demand in sensitive-skin, body-care, and baby-care lines. Kenvue posted $15.5 billion in net sales in 2024, giving Aveeno the scale to matter in the portfolio. That mix of reach and steady category demand supports Star status.
Zyrtec, allergy relief
Zyrtec is a key Kenvue allergy brand in a recurring OTC category that serves over 100 million Americans with allergies each year. Seasonal demand and heavy spring marketing support repeat buys, while strong brand recall helps defend share. That mix of scale, resilience, and repeat use makes Zyrtec a clear Star candidate in the BCG matrix.
Nicorette, smoking cessation
Nicorette fits Kenvue Inc.'s "Star" slot: nicotine-replacement demand stays tied to quitting, and WHO still links tobacco to over 8 million deaths a year. Pharmacy shelf space, repeat use, and strong brand trust support steady sell-through, so Kenvue can keep investing in distribution and consumer education.
- Quitting demand stays structurally high
- Pharmacy placement drives visibility
- Repeat purchase supports revenue
- Brand trust helps defend share
Rogaine, hair regrowth
Rogaine stays a top OTC hair-regrowth brand for Kenvue Inc., with strong consumer recall and broad male and female use. The hair-loss care market keeps widening as premium minoxidil and scalp-care formats expand, so Rogaine can fit "Star" logic if regrowth growth stays above Kenvue Inc.'s portfolio average.
- High awareness
- Premium formats grow
- Star if above-average growth
Kenvue’s Star Brands Power $15.5B in 2025 Sales
Neutrogena, Aveeno, Zyrtec, Nicorette, and Rogaine are Kenvue Inc. Star-like brands because they pair strong market demand with scale and shelf power. Kenvue Inc. reported 2025 net sales of $15.5 billion, and these brands help keep growth visible in skin care, allergy, quit-smoking, and hair regrowth.
| Brand | Star driver |
|---|---|
| Neutrogena | Premium skin care |
| Zyrtec | Repeat allergy demand |
What is included in the product
Detailed Word Document
Kenvue’s BCG Matrix maps its brands into Stars, Cash Cows, Question Marks, and Dogs to guide invest, hold, or divest decisions.
Editable Excel File
Clear BCG snapshot of Kenvue’s brands to spot cash cows, stars, and drag quickly.
Reference Sources
Shows the credible sources behind Kenvue Inc. assumptions, making the analysis easier to trust, verify, and use for decisions.
Cash Cows
Tylenol, No. 1 U.S. OTC pain reliever
Tylenol is a core Cash Cow for Kenvue: it sits in a mature U.S. OTC pain market, so heavy promo spend is not needed to defend demand. Kenvue reported 2024 net sales of about $15.5 billion, and Tylenol’s high brand equity helps keep that cash flowing with low reinvestment. In BCG terms, it is a classic steady generator, not a growth engine.
Listerine, leading mouthwash brand
Listerine is Kenvue’s cash cow: a top oral rinse brand in a mature oral care market, with daily repeat use and broad retail reach. Kenvue reported 2025 net sales of about $15.4 billion, and brands like Listerine help support stable margins and steady cash flow. Its scale and shelf presence keep demand resilient even in slow growth.
Band-Aid, leading adhesive bandage brand
Band-Aid is one of the most recognizable wound-care brands, with Kenvue Inc. reporting 2024 net sales of $15.5 billion. The category grows slowly, but Band-Aid’s wide household reach and repeat purchase behavior keep it a steady Cash Cow with low capital needs and reliable cash generation.
Johnson’s Baby, global baby care
Johnson’s Baby is a long-running Kenvue brand with wide global awareness, and baby care tends to be stable rather than high-growth, so it can keep generating steady cash. Its mature position, plus brand trust built over decades, fits the Cash Cow quadrant: low growth, strong share, and recurring demand. Kenvue does not break out Johnson’s Baby revenue, but the brand’s reach across many markets supports dependable cash flow.
- Strong global brand recognition
- Steady, recurring baby-care demand
- Mature market, low growth
- Fits Cash Cow positioning
Benadryl, established allergy brand
Benadryl is a legacy OTC allergy brand with strong name recognition, so it keeps pulling steady demand for Kenvue Inc. The allergy category is mature and crowded, which limits volume growth and keeps pricing pressure high. That mix of scale, trust, and low growth fits Cash Cow behavior.
- High brand awareness
- Low category growth
- Steady cash generation
- Heavy competition
Kenvue’s Cash Cows Keep the Revenue Engine Running
Kenvue’s Cash Cows are mature, low-growth brands that throw off steady cash. In 2025, Kenvue reported net sales of about $15.4 billion, and Tylenol, Listerine, Band-Aid, Johnson’s Baby, and Benadryl help sustain that base through repeat demand, strong shelf space, and trusted names.
| Brand | Role | Signal |
|---|---|---|
| Tylenol | Cash Cow | High equity |
| Listerine | Cash Cow | Repeat use |
| Band-Aid | Cash Cow | Low capex |
Full Version Awaits
Kenvue Inc. Reference Sources
The Kenvue Inc. BCG Matrix preview you see here is the exact same document you’ll receive after purchase. It’s a fully formatted, ready-to-use report with no hidden changes or demo content. Download it instantly and use it for strategy, analysis, or presentation. What you preview is what you get.
Dogs
Clean & Clear, value acne care
Clean & Clear fits Kenvue Inc.’s Dog box: it plays in a crowded acne aisle where buyers can choose fast-growing, dermatologist-led and premium brands instead. Acne is still a huge market, with acne affecting about 50 million Americans each year, but Clean & Clear has little share momentum versus higher-end skin care lines. So it looks like a low-growth, lower-share asset that likely needs either a reset or a harvest plan.
Bengay, topical analgesic
Bengay sits in a slow-growing topical pain market, and it does not have the scale of Kenvue’s larger pain brands. Kenvue reported 2024 net sales of $15.5 billion, but Bengay’s modest share and limited growth keep it near Dog status in the BCG Matrix. The brand’s role is niche, not a major profit driver.
OGX, mass hair care
OGX is a Dog in Kenvue Inc.'s BCG Matrix: shampoo and conditioner is a huge but crowded category, and shelf space is driven by heavy promos and price cuts. Big rivals like Procter & Gamble, Unilever, and L'Oréal keep the share fight intense, so smaller brands often stay stuck with weak growth. That makes OGX a low-share, low-momentum asset.
Carefree, feminine care
Carefree sits in Kenvue Inc.'s mature feminine-care niche, where growth is slow and rivals like Procter & Gamble and Kimberly-Clark keep pressure high. Kenvue reported 2025 net sales of about $15.5 billion, but Carefree adds little scale and has limited pricing power, which fits a Dog in the BCG matrix.
- Low growth
- Heavy competition
- Weak differentiation
- Dog classification
o.b., tampon brand
o.b. is a niche feminine-care brand inside Kenvue Inc.’s Essential Health portfolio, but it plays in a mature category with limited growth and no disclosed standalone sales. Larger rivals and private label keep pricing and shelf space tight, so o.b. lacks the scale needed to drive meaningful share gains. That makes it a classic Dog in the BCG Matrix.
- Low growth
- Weak scale
- Heavy share pressure
- Dog classification
Kenvue’s Dog Brands Face Low Growth and Tough Competition
Clean & Clear, Bengay, OGX, Carefree, and o.b. fit the Dog box in Kenvue Inc.’s BCG Matrix: each sits in a mature, crowded category with weak share momentum. Kenvue’s 2025 net sales were about $15.5 billion, but these brands add limited scale and face strong rivals like Procter & Gamble, Unilever, Kimberly-Clark, and L’Oréal. That points to low growth, low share, and either reset or harvest choices.
| Brand | Why Dog |
|---|---|
| Clean & Clear | Low share in acne |
| Bengay | Niche pain brand |
| OGX | Weak share in hair care |
| Carefree | Slow-growth feminine care |
| o.b. | Limited scale, mature market |
Question Marks
Motrin, ibuprofen pain relief
Motrin still matters in OTC pain relief, but it is far behind bigger leaders like Advil and Tylenol, so its share upside is uneven. Kenvue’s FY2025 base was about $15.5 billion in net sales, yet OTC pain is a huge but mature category, which makes share gains hard to buy. That is why Motrin fits a Question Mark: relevant, but with limited proof of scalable growth versus premium skin care.
Pepcid, heartburn relief
Pepcid still rides steady demand in acid relief and digestive care, a category Kenvue says keeps growing as consumers self-treat heartburn. But its share is more contested than Kenvue’s larger brands, so leadership is not clear. That makes Pepcid a Question Mark: real upside, but not yet dominant.
Stayfree, menstrual care
Stayfree sits in a steady menstrual-care category with roughly 500 million women menstruating each month worldwide, so demand is durable and recurring.
But larger players like Procter & Gamble and Kimberly-Clark dominate shelf space and ad spend, keeping Stayfree’s share under pressure.
That mix of stable demand, active product innovation, and weaker scale makes Stayfree a clear Question Mark in Kenvue Inc.’s BCG Matrix.
Nicoderm, nicotine patch
Nicoderm sits in a small but steady smoking-cessation market: the CDC said 11.6% of U.S. adults, or 28.8 million people, still smoked in 2023. As a nicotine patch, it can benefit if quit attempts rise, but the patch format trails Nicorette’s oral products in visibility and shelf pull. That mix makes Nicoderm a Question Mark with upside if Kenvue lifts share.
- Small niche, not a leader
- Quits can lift demand
- Patch share trails oral forms
- Upside depends on execution
Neosporin, wound treatment
Neosporin fits Question Mark status because wound treatment is a mature, crowded OTC niche, and use is mostly occasional rather than repeat-driven. Even with strong brand recognition in first-aid care, Kenvue needs more share gains and clearer growth to move it beyond a low-frequency category.
- Strong awareness, weak repeat use
- Mature market limits fast expansion
- Share gains are still the key test
Kenvue’s OTC Brands: Demand Exists, Leadership Doesn’t
Motrin, Pepcid, Stayfree, Nicoderm, and Neosporin are Kenvue Inc. Question Marks: each has real demand, but none has clear category leadership. FY2025 net sales were about $15.5 billion, yet these brands sit in crowded, mature OTC niches where share gains need heavy execution. Their upside is possible, but not proven.
| Brand | Signal |
|---|---|
| Motrin | Weak share |
| Pepcid | Contested |
| Stayfree | Scale gap |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.